<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874156</url>
  </required_header>
  <id_info>
    <org_study_id>REK 2018/2302</org_study_id>
    <nct_id>NCT03874156</nct_id>
  </id_info>
  <brief_title>MUscle Side-Effects of Atorvastatin in Coronary Patients</brief_title>
  <acronym>MUSE</acronym>
  <official_title>MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vestre Viken Hospital Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to estimate the effect of atorvastatin on muscular symptom intensity in
      coronary patients with subjective statin-associated muscle symptoms (SAMS) and to determine
      the association with blood levels of atorvastatin and its metabolites, to obtain an objective
      marker for true SAMS. A randomized study will include 80 coronary patients with SAMS during
      ongoing atorvastatin therapy or previous muscle symptoms that led to discontinuation of
      atorvastatin. Patients will be randomized to 7-weeks treatment with atorvastatin 40 mg/day in
      the first period and matched placebo in the second 7-weeks period, or placebo in the first
      period and atorvastatin in the second period. A control group (n=40) without muscle symptoms
      will have 7 weeks open treatment with atorvastatin 40 mg/day. Blood samples will be collected
      at baseline and after each treatment period, and muscular symptom intensities will be rated
      by the patients weekly. The primary outcome is the difference in aggregated mean Visual
      Analogue Scale (VAS) scores between the last three weeks of atorvastatin treatment and of
      placebo treatment. The main purpose is to develop an objective marker for true SAMS, by
      comparing SAMS associated with blinded atorvastatin treatment with blood concentrations of
      atorvastatin and its metabolites. Diagnostic and discrimination performance will be
      determined. The study provides new clinical knowledge on SAMS in coronary patients and may
      contribute to more personalized statin treatment and monitoring, fewer side-effects and
      consequently improved adherence and lipid management in future practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Actual">December 12, 2019</completion_date>
  <primary_completion_date type="Actual">December 12, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized double-blinded placebo controlled cross-over phase 4 study.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual mean difference in muscular symptom intensity measured with a 0 (no symptoms) to 10 (worst imaginable symptoms) Visual Analogue Scale (VAS) score between treatment periods with statin and placebo</measure>
    <time_frame>16 weeks following randomization</time_frame>
    <description>Individual mean difference in muscular symptom (i.e. pain, aching, tenderness, stiffness, cramp and/or weakness) intensity between treatment periods with statin and placebo, reported by the patients over the last three weeks (i.e. week 4-7) measured with a 0 (no symptoms) to 10 (worst imaginable symptoms) Visual Analogue Scale (VAS) score with aggregated data from each subscale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who report muscle symptoms on atorvastatin treatment and not on placebo (dichotomous Statin Associated Muscle Symptom classification)</measure>
    <time_frame>16 weeks following randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between individual muscular symptom intensity between treatment periods with statin and placebo over the last three weeks measured with 0 to 10 VAS score aggregated from each subscale, and levels of atorvastatin and metabolites</measure>
    <time_frame>16 weeks following randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity, and area under the curve of blood concentrations of parent drug and the active metabolites of atorvastatin for the classification of true Statin Associated Muscle Symptoms (SAMS)</measure>
    <time_frame>16 weeks following randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual mean difference in likelihood of statin discontinuation between treatment periods with statin and placebo over the last three weeks (i.e. week 4-7) measured with 0 to 10 VAS score with aggregated data from each subscale.</measure>
    <time_frame>16 weeks following randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statin adherence measured weekly with self-reported questionnaire methods during the study periods</measure>
    <time_frame>16 weeks following randomization</time_frame>
    <description>Statin adherence measured with self-reported questionnaires (numeric scale: &lt;4/7, 5/7, 6/7 or 7/7) weekly during the treatment periods. Low statin adherence will be defined by taking statins less than 42 of 49 days during the 7 weeks treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statin adherence measured with pill counts of returned packages</measure>
    <time_frame>16 weeks following randomization</time_frame>
    <description>Statin adherence measured with pill counts of returned packages. Low statin adherence will be defined by a total of &gt;=8 returned pills during the treatment periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statin adherence measured with direct liquid chromatography-tandem mass spectrometry methods</measure>
    <time_frame>16 weeks following randomization</time_frame>
    <description>Statin adherence measured with direct liquid chromatography-tandem mass spectrometry methods. Low statin adherence defined by dose-normalized statin and metabolites concentrations &lt; 0.10 (nmol/L)/mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of atorvastatin and its metabolites in blood plasma and white blood cells at study end</measure>
    <time_frame>16 weeks following randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with new-onset coronary heart disease symptoms, intolerable muscle symptoms leading to discontinuation from the treatment arm, and elevated levels of creatine kinase (CK) and/or Alanine Aminotransferase (ALT) in blood</measure>
    <time_frame>16 weeks following randomization</time_frame>
    <description>Safety endpoints: i.New-onset coronary heart disease symptoms. ii Intolerable muscle symptoms leading to discontinuation from the treatment arm.iii elevated levels of creatine kinase (CK) and/or Alanine Aminotransferase (ALT) in blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Statin Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 40 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo tablet once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 40mg</intervention_name>
    <description>Oral tablet fabricated and labelled at Krageroe Tablettproduksjon AS</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  First or recurrent diagnosis (myocardial infarction) or treatments (Percutaneous
             Coronary Intervention [PCI] or Coronary Artery Bypass Graft operation [CABG]) for a
             coronary heart disease (CHD) event at least 6 months prior to study start and
             prescribed atorvastatin (irrespective of dose)

          -  Reporting muscle complaints (i.e. pain, weakness, tenderness, stiffness or cramp) that
             they attribute to atorvastatin therapy or atorvastatin discontinuation due to muscle
             complains

          -  Signed informed consent and expected cooperation of the patient according to
             International Council for Harmonisation/Good Clinical Practice and national/local
             regulations

        Exclusion Criteria:

          -  First or recurrent diagnosis (myocardial infarction) or treatments (PCI or CABG) for a
             CHD event the a) past 12 months prior to study start in high risk patients (i.e. at
             least one of following comorbid conditions: systolic heart failure, &gt;1 previous
             myocardial infarction, kidney failure, diabetes, and smokers) and b) the past 6 months
             prior to study start in low risk patients without any of the co-morbid conditions
             mentioned above and in patients who are not taking a statin at all

             . Patients with symptomatic peripheral artery disease and patients with familial
             hypercholesterolemia

          -  Patient has any contraindications for atorvastatin listed in the Summary of Product
             Characteristics (i.e. known hypersensitivity to the ingredients, acute liver failure/
             Alanine Aminotransferase &gt; 3 times upper limit of the normal range in blood at study
             start, pregnancy and breastfeeding)

          -  History of previous rhabdomyolysis, myopathy or liver failure due to statin treatment
             with Creatine Kinase &gt; 10 times upper limit of the normal range or Alanine
             Aminotransferase &gt; 3 times upper limit of the normal range.

          -  Any condition (e.g. psychiatric illness, dementia) or situation, that in the
             investigator's opinion could put the subject at significant risk, confound the study
             results, interfere significantly with the subject participation in the study, or
             rendering informed consent unfeasible

          -  Short life expectancy (&lt;12 months) due to other medical conditions

          -  Not being able to understand Norwegian.

          -  Women of childbearing potential defined as all premenopausal female.

          -  Participation in another randomized clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>john munkhaugen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vestre Viken Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vestre Viken Trust, Drammen Hospital</name>
      <address>
        <city>Drammen</city>
        <state>Buskerud</state>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Vestfold Trust</name>
      <address>
        <city>TÃ¸nsberg</city>
        <state>Vestfold</state>
        <zip>3103</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>January 1, 2020</last_update_submitted>
  <last_update_submitted_qc>January 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data will be made available for other researchers</ipd_description>
    <ipd_time_frame>Data will be available within 5 years of study completion</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03874156/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03874156/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

